Phase II study of intermediate‐dose cytarabine in patients with relapsed or refractory Ewing sarcoma: A report from the Children's Oncology Group
- 8 January 2009
- journal article
- research article
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 52 (3), 324-327
- https://doi.org/10.1002/pbc.21822
Abstract
Background Patients with relapsed or refractory Ewing sarcoma have a poor outcome with conventional therapies. Cytarabine decreases EWS/FLI1 protein levels in Ewing sarcoma cells and has demonstrated preclinical activity against Ewing sarcoma in vitro and in vivo. The purpose of this phase II clinical trial was to estimate the response rate of intermediate‐dose cytarabine in patients with relapsed or refractory Ewing sarcoma. Procedure Patients with a histologic diagnosis of Ewing sarcoma were eligible if they were 2/dose intravenously over 2 hr every 12 hr for 10 doses with cycles repeated every 21 days. Response was assessed according to RECIST criteria. Results Ten patients (median age 20 years; 7 males) were treated. Only five patients had documented EWS /FLI1 translocated tumors. No objective responses were seen. One patient had stable disease for 5 cycles before developing progressive disease. All patients evaluable for hematologic toxicity developed grade 4 neutropenia and thrombocytopenia during protocol therapy. Patients were not able to receive therapy according to the planned 21‐day cycles, with a median interval of 26.5 days. Conclusions Cytarabine at the dose and schedule utilized in this trial resulted in hematologic toxicity that limited delivery of this therapy. This regimen also had minimal activity in this patient population. Pediatr Blood Cancer 2009;52:324–327.Keywords
This publication has 20 references indexed in Scilit:
- Combination of gemcitabine and docetaxel in the treatment of children and young adults with refractory bone sarcomaCancer, 2008
- Signature-Based Small Molecule Screening Identifies Cytosine Arabinoside as an EWS/FLI Modulator in Ewing SarcomaPLoS Medicine, 2007
- Phase II study of gemcitabine in children with solid tumors of mesenchymal and embryonic originAnti-Cancer Drugs, 2006
- Survival After Recurrence of Ewing’s Sarcoma Family of TumorsJournal of Clinical Oncology, 2005
- Outcome after relapse in an unselected cohort of children and adolescents with Ewing sarcomaMedical and Pediatric Oncology, 2003
- Survival after recurrence of Ewing TumorsCancer, 2002
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000
- Insulin-like growth factor-I-dependent growth and in vitro chemosensitivity of Ewing's sarcoma and peripheral primitive neuroectodermal tumour cell linesEuropean Journal of Cancer, 1993
- Pharmacokinetic Studies of Intermediate- to High-Dose 1-β-D-Arabinofuranosylcytosine in Children With Acute Leukemia and LymphomaThe Journal of Clinical Pharmacology, 1987
- Treatment of childhood acute lymphoblastic leukemia with intermediate‐dose cytosine arabinoside and adriamycinMedical and Pediatric Oncology, 1986